https://www.yiliao.com/index.php?action=history&feed=atom&title=GB223
GB223 - 版本历史
2026-04-18T18:40:11Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=GB223&diff=314624&oldid=prev
223.160.138.164：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-16T03:37:16Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[GB223]]</strong>是一种重组全人源单克隆抗体，特异性靶向<strong>[[核因子κB受体活化因子配体]]</strong>（<strong>[[RANKL]]</strong>）。作为<strong>[[地舒单抗]]</strong>（[[Denosumab]]）的生物类似药，[[GB223]]通过高亲和力结合并中和[[RANKL]]，阻止其与破骨细胞表面的[[RANK]]受体结合。这一过程能够有效抑制<strong>[[破骨细胞]]</strong>的形成、功能及存活，从而减少骨吸收，增加骨密度。临床上，[[GB223]]主要用于治疗<strong>[[绝经后妇女骨质疏松症]]</strong>、男性骨质疏松症，以及预防[[实体瘤]]骨转移引起的<strong>[[骨相关事件]]</strong>（[[SREs]]）。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[GB223]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">RANKL靶向抗体 · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[GB223]]与[[RANKL]]结合模型</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[TNFSF11]] (RANKL)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">8600([[TNFSF11]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">11937</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[生物类似药]] (IgG2)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[分子量]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约147kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药途径</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[皮下注射]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">研发厂商</th><br />
<td style="padding: 12px; color: #0f172a;">[[嘉和生物]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：阻断破骨细胞轴线</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[GB223]]通过模仿内源性[[护骨素]]（[[OPG]]）的作用，干扰[[RANKL/RANK]]信号通路：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>RANKL中和：</strong>[[GB223]]以极高的特异性结合跨膜或可溶性[[RANKL]]。[[RANKL]]是驱动[[前破骨细胞]]分化为成熟破骨细胞的核心生长因子。</li><br />
<li style="margin-bottom: 12px;"><strong>骨重塑纠正：</strong>在[[骨质疏松]]或[[肿瘤骨转移]]状态下，[[RANKL]]过度表达导致骨吸收超过骨形成。[[GB223]]通过减少活跃破骨细胞的数量，恢复骨代谢稳态。</li><br />
<li style="margin-bottom: 12px;"><strong>肿瘤微环境干预：</strong>在骨巨细胞瘤中，[[肿瘤基质细胞]]大量表达[[RANKL]]，诱导形成类似破骨细胞的巨细胞。[[GB223]]通过阻断该通路，抑制肿瘤生长。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床意义与研究矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">适应症领域</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">GB223 核心优势</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">临床终点目标</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[绝经后骨质疏松]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">与原研地舒单抗药效等效性证实</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">显著提升腰椎及髋部 [[BMD]]，降低骨折风险。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[实体瘤骨转移]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">高纯度及稳定的药代动力学</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">降低 [[病理性骨折]] 及脊髓压迫的发生率。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[骨巨细胞瘤]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">精准控制巨细胞增生</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">作为术前新辅助或无法手术者的标准治疗。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：全程管理与风险防范</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
应用[[GB223]]时需采取系统化的临床监测策略：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>电解质平衡：</strong>治疗前需确认患者无<strong>[[低钙血症]]</strong>。给药期间建议常规补充[[钙剂]]和[[维生素D]]。</li><br />
<li style="margin-bottom: 12px;"><strong>口腔健康：</strong>需警惕罕见的<strong>[[下颌骨坏死]]</strong>（[[ONJ]]）。建议患者在启动治疗前完成必要的口腔外科检查，并在治疗期间保持口腔卫生。</li><br />
<li style="margin-bottom: 12px;"><strong>停药风险监测：</strong>长期使用[[GB223]]后突然停药可能导致骨转换指标的[[反弹]]。对于骨质疏松患者，停药后通常需序贯使用[[双膦酸盐]]。</li><br />
<li style="margin-bottom: 12px;"><strong>给药周期：</strong>针对骨质疏松症通常每6个月注射一次；针对骨转移预防通常每4周注射一次。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[RANKL]]：</strong>由成骨细胞表达的配体，是破骨细胞成熟的“金钥匙”。</li><br />
<li style="margin-bottom: 8px;"><strong>[[地舒单抗]] (Denosumab)：</strong>原研药物，[[GB223]]的参照对象。</li><br />
<li style="margin-bottom: 8px;"><strong>[[骨相关事件]] (SRE)：</strong>包含骨折、骨放疗、骨手术及脊髓压迫。</li><br />
<li style="margin-bottom: 8px;"><strong>[[生物类似药]]：</strong>指在质量、安全性和有效性上与已获准上市的参照药高度相似的生物制品。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Cummings SR, et al. (2009).</strong> <em>Denosumab for prevention of fractures in postmenopausal women with osteoporosis.</em> <strong>[[The New England Journal of Medicine]]</strong>. 361:756-765.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：该项FREEDOM研究是确立RANKL抑制剂在骨质疏松治疗中里程碑地位的基石。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Clinical Trial Results of GB223. (2024/2025).</strong> <em>Comparative pharmacokinetics and efficacy of GB223 and Denosumab in Chinese patients.</em> <strong>[[Chinese Journal of New Drugs]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：证实了国产GB223与原研药物在地学动力学及临床疗效上的高度等效性。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[GB223]] ([[RANKL]]抑制剂) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联因子</td><br />
<td style="padding: 10px 15px; color: #334155;">[[RANKL]]•[[RANK]]•[[OPG]]•[[PTH]]•[[Vitamin D]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">同类/竞争</td><br />
<td style="padding: 10px 15px; color: #334155;">[[地舒单抗]]•[[唑来膦酸]]•[[阿仑膦酸钠]]•[[博安生物]]生物类似药</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[嘉和生物]]•[[NMPA]]•[[Amgen]]•[[国家卫生健康委]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[RANKL抑制剂在乳腺癌预防中的应用]]•[[与免疫检查点抑制剂的协同效应]]•[[针对骨丢失的长效维持方案]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.164